Edwards Lifesciences EW NYSE · Healthcare · United States
$103.90 -1.26% -$1.33
Summary
59 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 15 USD is left as net profit.
- It holds more cash than debt: $3.11B against $704.5M.
- Analysts expect revenue to grow by 12% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share fell by 9.1% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBy our assumptions the business is worth less than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 59.2 USD for 1 USD of yearly profit. Over the last five years it was 35.1 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 6.7% a year over 5 years. Over the last 3 years it grew by 4.1% a year. For the next fiscal year analysts expect revenue to grow by 12%. Earnings per share fell by 9.1% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 22 USD
- Research and development 16 USD
- Sales and administration 36 USD
- Taxes and other 10 USD
- Net profit 15 USD
Net profit, industry median (Medical - Devices) 6.9 USD
Out of every 100 USD of revenue, 15 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 34
- Hold 15
- Sell 0
Today's price within the analysts' price targets
The average target of $106.13 is 2.1% above today's price. 69% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Transcatheter Heart Valves 74%
- Surgical Heart Valve Therapy 17%
- Transcatheter Mitral And Tricuspid Therapies 9.1%
By region
- UNITED STATES 58%
- Europe 25%
- Rest of World 11%
- JAPAN 5.8%
Transcatheter Heart Valves brings in 74% of revenue. Transcatheter Mitral And Tricuspid Therapies grew fastest, by 59% a year.
Segments in detail